Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | GABRP | O00591 | 2/20 | 0.40 |
| ▸ | GABRD | O14764 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.40 |
| ▸ | GABRE | P78334 | 2/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.40 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.40 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.40 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4474507 | 0.78 | PTK2 (0.45) | NPC1RAB9ATP53SMN1; SMN2CHRM2 | |
| SCHEMBL17336767 | 0.78 | NPC1 (0.47) | ALDH1A1NPC1RAB9AGABRPGABRD | |
| SCHEMBL2722927 | 0.77 | CYP2A6 (0.48) | ALDH1A1TP53SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL674221 | 0.76 | CHRM2 (0.50) | ALDH1A1MAPK1NPC1RAB9AGABRP | |
| SCHEMBL5307132 | 0.73 | NPC1 (0.43) | ALDH1A1NPC1RAB9ATDP1TP53 | |
| SCHEMBL27746605 | 0.73 | RAB9A (0.38) | ALDH1A1NPC1RAB9AGABRPGABRD | |
| SCHEMBL14848480 | 0.73 | RAB9A (0.38) | ALDH1A1NPC1RAB9AGABRPGABRD | |
| SCHEMBL15316365 | 0.73 | MAOB (0.44) | ALDH1A1NPC1RAB9AMAOBTP53 | |
| SCHEMBL4466746 | 0.70 | KDM4E (0.46) | ALDH1A1MAPK1NPC1RAB9ATDP1 | |
| SCHEMBL3972917 | 0.70 | NR4A2 (0.64) | ALDH1A1NPC1RAB9ATP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2681207-B1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2016-12-28 | — | — | EP | disclosed |
| US-8912188-B2 | Substituted quinoxaline carboxylic acids for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912188-B2 | Substituted quinoxaline carboxylic acids for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912188-B2 | Substituted quinoxaline carboxylic acids for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| EP-2681207-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | Bioenergenix (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20120232056-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232056-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232056-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-09-13 | — | — | US | disclosed |
| WO-2012119046-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-09-07 | — | — | WO | disclosed |
| WO-2012119046-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232056-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | ALDH1A1 3714/4885MAPK1 574/4885NPC1 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.